ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2024
Open access · hybridAbstract readMulticenter Study
In one paragraph
Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 77 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
77citing papers in PubMed, 2 pooled it
57.9field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
77 citing papers in PubMed, 2 syntheses or guidelines pooled it, 101 citations in OpenAlex.
- FGFR3 Alterations and Nectin-4 Expression as Therapeutic Biomarkers in Bladder Cancer: A Systematic Review and Single-Arm Meta-Analysis.International journal of molecular sciences · 2026Pooled it
- Antibody-Drug Conjugates for Locally Advanced and Metastatic Urothelial Carcinoma: A Systematic Review and Meta-Analysis.JAMA network open · 2026Pooled it
- First-in-Human, Phase I/II Dose Escalation and Expansion Study of Zelenectide Pevedotin in Patients With Advanced Solid Tumors: Results From Monotherapy Dose Escalation.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025Trial
- Advancing antibody drug conjugates in gastrointestinal cancers.British journal of cancer · 2026Review
- Prognostic value and diagnostic performance of nectin-4-targeted [European journal of nuclear medicine and molecular imaging · 2026Article
- Toxicity, Dose Intensity, and Clinical Outcomes with First-Line Enfortumab Vedotin Plus Pembrolizumab in Advanced Urothelial Carcinoma: A Multicenter Real-World Study.Current oncology (Toronto, Ont.) · 2026Observational
- Article
- Article
- Integrating clinically actionable biomarkers into bladder cancer care - recommendations from the International Bladder Cancer Group.Nature reviews. Urology · 2026Review
- Evaluation of HER2 and Nectin-4 Expression in Primary Vaginal Cancers.International journal of molecular sciences · 2026Article
- [Diagnostic and predictive molecular pathology of urothelial carcinoma : Current status and outlook for the future].Pathologie (Heidelberg, Germany) · 2026Review
- Spatial Multiomics Reveal Insights Into ADC Efficacy.European journal of immunology · 2026Review
- Bioinformatics profiling of NECTIN4 in lung cancer and comparative evaluation of NECTIN4-targeted ⁶⁸Ga-N188 and ¹⁸F-FDG PET/CT.Journal of translational medicine · 2026Article
- Article
- Nectin-4 expression in vulvar squamous cell carcinoma.Virchows Archiv : an international journal of pathology · 2026Article
- Novel Immune Checkpoint Inhibitor and Antibody-Drug Conjugate Approaches in the Perioperative Management of Muscle-Invasive Bladder Cancer.Current oncology (Toronto, Ont.) · 2026Review
- The changing landscape of urothelial carcinoma: on the edge of a paradigm shift.The Journal of clinical investigation · 2026Review
- Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107.Molecular oncology · 2026Article
- Biomarkers and testing in pathology.Current opinion in urology · 2026Review
- [From nontargeted to precision oncology: predictive biomarkers and targeted therapies in advanced urothelial carcinoma].Urologie (Heidelberg, Germany) · 2026Article
17 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
41 authors at 19 institutions in 4 countries.
Niklas KlümperDepartment of Urology and Pediatric Urology, University Hospital Bonn, Bonn, Germany.ORCID 0000-0002-3258-0586
Ngoc Khanh TranDepartment of Urology and Pediatric Urology, University Hospital Bonn, Bonn, Germany.ORCID 0009-0008-9612-1056
Stefanie ZschäbitzDepartment of Medical Oncology, National Center for Tumor Disease (NCT), University Hospital, Heidelberg, Germany.
Oliver HahnDepartment of Urology and Pediatric Urology, Julius Maximilians University Medical Center of Würzburg, Würzburg, Germany.ORCID 0000-0002-8864-2491
Thomas BüttnerDepartment of Urology and Pediatric Urology, University Hospital Bonn, Bonn, Germany.ORCID 0000-0003-0316-9621
Florian RoghmannBRIDGE-Consortium Germany e.V., Mannheim, Germany.
Christian BolenzBRIDGE-Consortium Germany e.V., Mannheim, Germany.
Friedemann ZengerlingBRIDGE-Consortium Germany e.V., Mannheim, Germany.
Constantin SchwabInstitute of Pathology, University of Heidelberg, Heidelberg, Germany.ORCID 0000-0002-0979-2943
Dora NagyCenter for Integrated Oncology Aachen/Bonn/Cologne/Düsseldorf (CIO-ABCD), Bonn, Germany.
Marieta TomaCenter for Integrated Oncology Aachen/Bonn/Cologne/Düsseldorf (CIO-ABCD), Bonn, Germany.ORCID 0000-0002-4803-3712
Glen KristiansenCenter for Integrated Oncology Aachen/Bonn/Cologne/Düsseldorf (CIO-ABCD), Bonn, Germany.
Hendrik HeersDepartment of Urology, University Hospital Marburg, Marburg, Germany.ORCID 0000-0002-7157-5077
Philipp IvanyiDepartment of Hemostaseology, Oncology and Stem Cell Transplantation, Medical University Hannover, Hannover, Germany.ORCID 0000-0002-2862-7302
Günter NiegischDepartment of Urology, University Hospital Düsseldorf, Düsseldorf, Germany.ORCID 0000-0001-6929-8691
Camilla Marisa GrunewaldDepartment of Urology, University Hospital Düsseldorf, Düsseldorf, Germany.ORCID 0000-0002-5069-3752
Christopher DarrDepartment of Urology, University Hospital Essen, Essen, Germany.ORCID 0000-0003-2532-8398
Arian FaridDepartment of Urology, University Medical Center Göttingen, Göttingen, Germany.
Katrin SchlackDepartment of Urology, University Hospital Münster, Münster, Germany.ORCID 0000-0001-5843-140X
Mahmoud AbbasDepartment of Pathology, University Hospital Münster, Münster, Germany.
Can AydogduDepartment of Urology, University Hospital, Ludwig Maximilian University of Munich, Munich, Germany.ORCID 0009-0003-1486-183X
Jozefina CasuscelliDepartment of Urology, University Hospital, Ludwig Maximilian University of Munich, Munich, Germany.
Theresa MokryDepartment of Diagnostic and Interventional Radiology, Heidelberg University Hospital, Heidelberg, Germany.ORCID 0000-0002-5997-5254
Michael MayrClinic Ottakring, Institute of Pathology and Microbiology, Wien, Austria.
Dora Niedersüß-BekeDepartment of Internal Medicine I, Wilhelminenspital, Wien, Austria.
Steffen RauschDepartment of Urology, Eberhard Karls University, Tübingen, Germany.ORCID 0000-0002-6398-8701
Dimo DietrichDepartment of Otorhinolaryngology, University Medical Center Bonn (UKB), Bonn, Germany.ORCID 0000-0001-9794-7927
Jonas SaalInstitute of Experimental Oncology, University Medical Center Bonn (UKB), Bonn, Germany.ORCID 0000-0002-9647-2947
Jörg EllingerDepartment of Urology and Pediatric Urology, University Hospital Bonn, Bonn, Germany.ORCID 0000-0002-7526-0857
Manuel RitterDepartment of Urology and Pediatric Urology, University Hospital Bonn, Bonn, Germany.ORCID 0000-0003-0619-0370
Abdullah AlajatiDepartment of Urology and Pediatric Urology, University Hospital Bonn, Bonn, Germany.
Christoph KuppeInstitute of Experimental Medicine and Systems Biology and Division of Nephrology, RWTH Aachen University, Aachen, Germany.ORCID 0000-0003-4597-9833
Joshua MeeksDepartment of Urology, Feinberg School of Medicine, Chicago, IL.ORCID 0000-0002-5444-5510
Francisco E Vera BadilloDepartment of Medical Oncology, Queen's University, Kingston, Ontario, Canada.ORCID 0000-0003-1068-3258
J Alberto Nakauma-GonzálezDepartment of Urology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands.ORCID 0000-0002-9153-4280
Joost BoormansDepartment of Urology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands.
Kerstin JunkerDepartment of Urology and Pediatric Urology, Saarland University, Homburg, Germany.ORCID 0000-0002-0873-8128
Arndt HartmannBRIDGE-Consortium Germany e.V., Mannheim, Germany.
Viktor GrünwaldClinic for Internal Medicine (Tumor Research) and Clinic for Urology, Interdisciplinary Genitourinary Oncology at the West-German Cancer Center, Essen University Hospital, Essen, Germany.ORCID 0000-0003-2083-7687
Michael HölzelInstitute of Experimental Oncology, University Medical Center Bonn (UKB), Bonn, Germany.ORCID 0000-0003-4048-8824
Markus EcksteinBRIDGE-Consortium Germany e.V., Mannheim, Germany.ORCID 0000-0001-5418-3349
University Hospital Bonn · DEHeidelberg University · DEDüsseldorf University Hospital · DEErasmus MC Cancer Institute · NLEssen University Hospital · DEFriedrich-Alexander-Universität Erlangen-Nürnberg · DELudwig-Maximilians-Universität München · DEUniversität Ulm · DEUniversity Hospital Münster · DEMedizinische Hochschule Hannover · DEPhilipps University of Marburg · DEQueen's University · CARWTH Aachen University · DESaarland University · DEUniversitätsklinik Marien Hospital Herne · DEUniversitätsmedizin Göttingen · DEUniversity of Tübingen · DEUniversity of Würzburg · DEWilhelminen Hospital · AT
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe anti-NECTIN4 antibody-drug conjugate enfortumab vedotin (EV) is approved for patients with metastatic urothelial cancer (mUC). However, durable benefit is only achieved in a small, yet uncharacterized patient subset. MATERIALS AND
methodsWe established a
results
conclusion
Indexed as
Cell Adhesion MoleculesGene AmplificationAgedAged, 80 and overAntibodies, MonoclonalBiomarkers, TumorDNA Copy Number VariationsFemaleHumansIn Situ Hybridization, FluorescenceMaleMiddle AgedNectinsUrinary Bladder NeoplasmsUrologic NeoplasmsAntibodies, MonoclonalBiomarkers, TumorCell Adhesion Moleculesenfortumab vedotinNECTIN4 protein, humanNectins
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.